Arnita F Avery, DPM in Atlanta, GA - Podiatrist

Arnita F Avery, DPM is a Podiatrist - Foot & Ankle Surgery physician based in Atlanta, Georgia. Arnita F Avery is licensed to practice in Georgia (license number 000632) and her current practice location is 5825 Glenridge Dr, Building 2, Suite 110, Atlanta, Georgia. She can be reached at her office (for appointments etc.) via phone at (404) 255-4900.

NPI number for Arnita F Avery is 1801998943 and her current mailing address is 5825 Glenridge Dr, Building 2, Suite 110, Atlanta, Georgia. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1801998943.

Contact Information

	Arnita F Avery, DPM
	5825 Glenridge Dr, Building 2, Suite 110, Atlanta, GA 30328-5387
	(404) 255-4900
	(404) 255-4899

Physician's Profile

Full Name	Arnita F Avery
Gender	Female
Speciality	Podiatrist - Foot & Ankle Surgery
Location	5825 Glenridge Dr, Atlanta, Georgia
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1801998943
Provider Enumeration Date: 09/01/2006
Last Update Date: 09/13/2016

Medical Identifiers

Medical identifiers for Arnita F Avery such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1801998943	NPI	-	NPPES
GRP6860	Other	GA	MEDICARE GROUP NUMBER

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208VP0000X	Pain Medicine - Pain Medicine	000632 (Georgia)	Secondary
213E00000X	Podiatrist	000632 (Georgia)	Secondary
213EP1101X	Podiatrist - Primary Podiatric Medicine	000632 (Georgia)	Secondary
213ER0200X	Podiatrist - Radiology	000632 (Georgia)	Secondary
213ES0000X	Podiatrist - Sports Medicine	000632 (Georgia)	Secondary
213ES0103X	Podiatrist - Foot & Ankle Surgery	000632 (Georgia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Arnita F Avery is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Arnita F Avery, DPM 5825 Glenridge Dr, Building 2, Suite 110, Atlanta, GA 30328-5387 Ph: (404) 255-4900	Arnita F Avery, DPM 5825 Glenridge Dr, Building 2, Suite 110, Atlanta, GA 30328-5387 Ph: (404) 255-4900

News Archive

Findings increase understanding of how an organism's body size is determined and how the speed of its development is controlled

In particular, the work sheds light on the molecular and cellular pathways that act to convey information about a growing organism's size, as well as on pathways that use that information to correctly time critical transitional events during development.

Researchers at NIH-FEI Living Lab for Structural Biology achieve breakthrough biological results

FEI is pleased to announce that researchers at the NIH-FEI Living Lab for Structural Biology have achieved breakthrough biological results, using FEI's Titan Krios™ transmission electron microscope (TEM), to elucidate the structural mechanism by which glutamate receptors participate in the transmission of signals between neurons in the brain. Their work is described in Nature, "Structural Mechanism of Glutamate Receptor Activation and Desensitization," by Meyerson, et al., (DOI: 10.1038/nature13603), http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13603.html .

DCPR classification provides diagnostic criteria to evaluate psychosomatic syndromes

An investigation headed by Piero Porcelli (Bari, Italy) has yielded new insights as to what affects how a patient perceives his/her illness. It is published in the current issue of Psychotherapy and Psychosomatics.

Rhythm abnormality of unknown origin strongly predicts sudden death risk in heart disease patients

Researchers conducting a large, ongoing study to improve detection and prevention of sudden cardiac death were surprised to discover that a specific heart rhythm abnormality – idiopathic QT interval prolongation – increased risk five-fold among patients with coronary artery disease.

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

Arnita F Avery, DPM - Podiatrist in Atlanta, GA